13324-11-3

Usage

Chemical Properties

almost beige powder

InChI:InChI=1/C8H6ClNO4/c1-14-8(11)6-3-2-5(10(12)13)4-7(6)9/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 99-60-5 2-chloro-4-nitrobenzoic acid 
• 598-99-2 Methyl trichloroacetate 
• 10369-82-1 2-(diethylamino)ethyl acetate 
• 10367-96-1 2-(diethylamino)ethyl 2-chloro-4-nitrobenzoate 
• 121-86-8 2-chloro-4-nitrotoluene 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 3240-34-4 [bis(acetoxy)iodo]benzene 
• 75-91-2 tert.-butylhydroperoxide 
• 619-50-1 4-nitrobenzoic acid methyl ester 
• 7073-36-1 2-chloro-4-nitrobenzoyl chloride 

Downstream Products

• 46004-37-9 methyl 4-amino-2-chlorobenzoate 
• 85953-29-3 methyl 2-chloro-4-fluorobenzoate 
• 250790-03-5 C₂₁H₁₇NO₅ 
• 65-85-0 benzoic acid 
• 137548-22-2 methyl 4-(acetylamino)-2-chlorobenzoate 
• 106125-46-6 methyl 4-(acetylamino)-2-chloro-5-nitrobenzoate 
• 1616257-07-8 methyl 4-amino-2-chloro-5-nitrobenzoate 
• 64617-64-7 methyl 4,5-diamino-2-chlorobenzoate 
• 67345-78-2 2-chloro-4-nitrobenzohydrazide 
• 879088-84-3 methyl 2-chloro-4-mercaptobenzoate 
• 116209-31-5 2-chloro-4-mercaptobenzoic acid 
• 1190947-66-0 methyl 2-chloro-4-(ethoxycarbonothioylthio)benzoate 
• 1628431-64-0 methyl 2-cyano-4-nitrobenzoate 

Relevant academic research and scientific papers

Synthesis of a coronene analogue containing an amide bond by Pd-mediated intramolecular C[sbnd]C bond formation of 2-halogenated 4-(alkylamino)benzoic acid cyclic trimer

A coronene analogue containing amide linkage was synthesized from a halogenated cyclic triamide by palladium-mediated intramolecular C[sbnd]C bond formation. The cyclic triamide was formed from the condensation of 2-chloro-4-(isobutylamino)benzoic acid in

NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA

The present invention relates to compounds having a structure of general formula (I), processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in humans and warm-blooded animals.

PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

Synthesis and trypanocidal activity of novel benzimidazole derivatives

The present work reports the synthesis and biological activity of a series of 14 benzimidazole derivatives designed to act on the enzyme triosephosphate isomerase of Trypanosoma cruzi (TcTIM). This enzyme is involved in the metabolism of glucose, the only source of energy for the parasite. In this study, we found four compounds that inhibit TcTIM moderately and lack inhibitory activity against human TIM (HsTIM). In vitro studies against T. cruzi epimastigotes showed two compounds that were more active than the reference drug nifurtimox, and these presented a low cytotoxic effect in mouse macrophages (J744 cell line).

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula (I) and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

Copper-catalyzed decarboxylative methylation of aromatic carboxylic acids with PhI(OAc)2

The copper-catalyzed decarboxylative methylation of aromatic carboxylic acids was developed by using PhI(OAc)2 to provide a new strategy for the methylation of aryl acids through the decarboxylation of alkyl acids. The mechanism and the roles of each reactant in the reaction were investigated extensively. Copyright

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH A CO-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a CO-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Copper-catalyzed methyl esterification reactions via C-C bond cleavage

The highly effective synthesis of methyl esters from benzylic alcohols, aldehydes, or acids via copper-catalyzed C-C cleavage from tert-butyl hydroperoxide is reported in this paper for the first time. Our protocol is easily accessible and practical, making it a possible supplement for the traditional way.